Merck, looking to build on cancer success, buys I-O biotech Rigontec

Merck could pay up to $500 million for the European biotech.

Merck is spending €115 million ($137 million) up front and up to €349 million in future payments to buy out German biotech Rigontec.

The Munich, Germany-based company is at work on accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a new approach in cancer immunotherapy.

The idea is to induce both immediate and long-term antitumor immunity; its leading candidate, RGT100, is in early clinical trials in patients with various tumors. More details on targets and financials were not given.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The early-stage company was founded back in 2014 as a spinout of the University Bonn in Germany, raising nearly €30 million in that time from a host of VCs, including Boehringer’s Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds, Wellington Partners Life Sciences and MP Healthcare Venture Management.

RELATED: Merck's Keytruda wins first FDA nod to treat genetically ID'd tumors anywhere in the body

Though not on the scale of Gilead's recent $11.9 billion buyout of CAR-T biotech Kite Pharma, Merck hopes this can add to its pipeline of cancer meds in a broader effort to shore up its future in I-O, coming after the commercial success of its checkpoint inhibitor Keytruda, which now has a series of FDA-approved uses across a number of cancers.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.